CORRECTION OF IMMATERIAL ERRORS (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2026 |
Dec. 31, 2025 |
| Correction Of Immaterial Errors [Abstract] |
|
|
| Schedule of unaudited condensed consolidated interim statement of operations [Table Text Block] |
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Research and development expenses |
|
- |
|
|
255,479 |
|
|
255,479 |
|
| Total operating expenses |
|
1,624,074 |
|
|
255,479 |
|
|
1,879,553 |
|
| Grant income |
|
- |
|
|
40,000 |
|
|
40,000 |
|
| Net loss |
|
2,437,628 |
|
|
215,479 |
|
|
2,653,107 |
|
| Loss per share |
|
0.12 |
|
|
0.01 |
|
|
0.13 |
|
|
Unaudited condensed consolidated interim statement of operations for the three months ended March 31, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Research and development expenses |
|
- |
|
|
255,479 |
|
|
255,479 |
|
| Total operating expenses |
|
1,624,074 |
|
|
255,479 |
|
|
1,879,553 |
|
| Net loss |
|
2,397,628 |
|
|
255,479 |
|
|
2,653,107 |
|
| Loss per share |
|
0.12 |
|
|
0.01 |
|
|
0.13 |
|
Unaudited condensed consolidated interim statement of operations for the three months ended June 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Business development expenses |
|
206,000 |
|
|
376,125 |
|
|
582,125 |
|
| Research and development expenses |
|
441,992 |
|
|
(255,479 |
) |
|
186,513 |
|
| Total operating expenses |
|
2,056,672 |
|
|
120,646 |
|
|
2,177,318 |
|
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Net loss |
|
1,813,781 |
|
|
120,646 |
|
|
1,934,427 |
|
| Loss per share |
|
0.09 |
|
|
- |
|
|
0.09 |
|
Unaudited condensed consolidated interim statement of operations for the six months ended June 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Business development expenses |
|
386,000 |
|
|
376,125 |
|
|
762,125 |
|
| Total operating expenses |
|
3,680,746 |
|
|
376,125 |
|
|
4,056,871 |
|
| Net loss |
|
4,211,409 |
|
|
376,125 |
|
|
4,587,534 |
|
| Loss per share |
|
0.21 |
|
|
0.02 |
|
|
0.23 |
|
Unaudited condensed consolidated interim statement of operations for the three months ended September 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Business development expenses |
|
194,736 |
|
|
472,500 |
|
|
667,236 |
|
| Consulting fees |
|
423,490 |
|
|
(100,000 |
) |
|
323,490 |
|
| Total operating expenses |
|
1,980,953 |
|
|
372,500 |
|
|
2,353,453 |
|
| Net loss |
|
2,049,910 |
|
|
372,500 |
|
|
2,422,410 |
|
| Loss per share |
|
0.09 |
|
|
0.03 |
|
|
0.12 |
|
Unaudited condensed consolidated interim statement of operations for the nine months ended September 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Business development expenses |
|
580,736 |
|
|
848,625 |
|
|
1,429,361 |
|
| Consulting fees |
|
1,189,450 |
|
|
(100,000 |
) |
|
1,089,450 |
|
| Total operating expenses |
|
5,661,699 |
|
|
748,625 |
|
|
6,410,324 |
|
| Net loss |
|
6,261,319 |
|
|
748,625 |
|
|
7,009,944 |
|
| Loss per share |
|
0.30 |
|
|
0.04 |
|
|
0.34 |
|
|
| Schedule of unaudited condensed consolidated balance sheet [Table Text Block] |
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Grant receivable |
|
- |
|
|
40,000 |
|
|
40,000 |
|
| Total current assets |
|
5,679,923 |
|
|
40,000 |
|
|
5,719,923 |
|
| Total assets |
|
12,601,612 |
|
|
40,000 |
|
|
12,641,612 |
|
| Accounts payable and accrued liabilities |
|
465,889 |
|
|
255,479 |
|
|
721,368 |
|
| Total current liabilities |
|
16,797,701 |
|
|
255,479 |
|
|
17,053,180 |
|
| Total liabilities |
|
16,934,303 |
|
|
255,479 |
|
|
17,189,782 |
|
| Accumulated deficit |
|
(19,324,443 |
) |
|
(215,479 |
) |
|
(19,539,922 |
) |
| Total stockholders' equity (deficit) |
|
(4,332,691 |
) |
|
(215,479 |
) |
|
(4,548,170 |
) |
|
Unaudited condensed consolidated balance sheet as of March 31, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Accounts payable and accrued liabilities |
|
465,889 |
|
|
255,479 |
|
|
721,368 |
|
| Total current liabilities |
|
16,797,701 |
|
|
255,479 |
|
|
17,053,180 |
|
| Total liabilities |
|
16,934,303 |
|
|
255,479 |
|
|
17,189,782 |
|
| Accumulated deficit |
|
(19,284,443 |
) |
|
(255,479 |
) |
|
(19,539,922 |
) |
| Total stockholders' equity (deficit) |
|
(4,292,691 |
) |
|
(255,479 |
) |
|
(4,548,170 |
) |
Unaudited condensed consolidated balance sheet as of June 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Accounts payable and accrued liabilities |
|
661,401 |
|
|
376,125 |
|
|
1,037,526 |
|
| Total current liabilities |
|
16,879,073 |
|
|
376,125 |
|
|
17,255,198 |
|
| Total liabilities |
|
16,988,849 |
|
|
376,125 |
|
|
17,364,974 |
|
| Accumulated deficit |
|
(21,098,224 |
) |
|
(376,125 |
) |
|
(21,474,349 |
) |
| Total stockholders' equity (deficit) |
|
(3,565,520 |
) |
|
(376,125 |
) |
|
(3,941,645 |
) |
Unaudited condensed consolidated balance sheet as of September 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Prepaid expenses |
|
294,287 |
|
|
100,000 |
|
|
394,287 |
|
| Total current assets |
|
4,451,683 |
|
|
100,000 |
|
|
4,551,683 |
|
| Total assets |
|
12,235,764 |
|
|
100,000 |
|
|
12,335,764 |
|
| Accounts payable and accrued liabilities |
|
1,098,683 |
|
|
848,625 |
|
|
1,947,308 |
|
| Total current liabilities |
|
17,642,168 |
|
|
848,625 |
|
|
18,490,793 |
|
| Total liabilities |
|
17,731,059 |
|
|
848,625 |
|
|
18,579,684 |
|
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Accumulated deficit |
|
(23,148,134 |
) |
|
(748,625 |
) |
|
(23,896,759 |
) |
| Total stockholders' equity (deficit) |
|
(5,495,295 |
) |
|
(748,625 |
) |
|
(6,243,920 |
) |
|
| Schedule of unaudited condensed consolidated statement of cash flows [Table Text Block] |
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Net loss for the year |
|
(2,437,628 |
) |
|
(215,479 |
) |
|
(2,653,107 |
) |
| Changes in non-cash working capital: Accounts payable and accrued liabilities |
|
(265,867 |
) |
|
255,479 |
|
|
(10,388 |
) |
| Grant receivable |
|
- |
|
|
(40,000 |
) |
|
(40,000 |
) |
| Net cash used in operating activities |
|
(1,669,732 |
) |
|
- |
|
|
(1,669,732 |
) |
|
Unaudited condensed consolidated statement of cash flows as of March 31, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Net loss for the year |
|
(2,397,628 |
) |
|
(255,479 |
) |
|
(2,653,107 |
) |
| Changes in non-cash working capital: Accounts payable and accrued liabilities |
|
(265,867 |
) |
|
255,479 |
|
|
(10,388 |
) |
| Net cash used in operating activities |
|
(1,669,732 |
) |
|
- |
|
|
(1,669,732 |
) |
Unaudited condensed consolidated statement of cash flows as of June 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Net loss for the year |
|
(4,211,409 |
) |
|
(376,125 |
) |
|
(4,587,534 |
) |
| Changes in non-cash working capital: Accounts payable and accrued liabilities |
|
(70,355 |
) |
|
376,125 |
|
|
305,770 |
|
| Net cash used in operating activities |
|
(3,488,588 |
) |
|
- |
|
|
(3,488,588 |
) |
Unaudited condensed consolidated statement of cash flows as of September 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Net loss for the year |
|
(6,261,319 |
) |
|
(748,625 |
) |
|
(7,009,944 |
) |
| Changes in non-cash working capital: Prepaid expenses |
|
(159,715 |
) |
|
(100,000 |
) |
|
(259,715 |
) |
| Accounts payable and accrued liabilities |
|
366,927 |
|
|
848,625 |
|
|
1,215,552 |
|
| Net cash used in operating activities |
|
(4,992,573 |
) |
|
- |
|
|
(4,992,573 |
) |
|
| Schedule of unaudited condensed consolidated interim statements of changes in stockholders' equity (deficit) [Table Text Block] |
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Accumulated deficit |
|
(19,324,443 |
) |
|
(215,479 |
) |
|
(19,539,922 |
) |
| Total stockholders' equity (deficit) |
|
(4,332,691 |
) |
|
(215,479 |
) |
|
(4,548,170 |
) |
|
Unaudited condensed consolidated interim statements of changes in stockholders' equity (deficit) as of March 31, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Accumulated deficit |
|
(19,284,443 |
) |
|
(255,479 |
) |
|
(19,539,922 |
) |
| Total stockholders' equity (deficit) |
|
(4,292,691 |
) |
|
(255,479 |
) |
|
(4,548,170 |
) |
Unaudited condensed consolidated interim statements of changes in stockholders' equity (deficit) as of June 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Accumulated deficit |
|
(21,098,224 |
) |
|
(376,125 |
) |
|
(21,474,349 |
) |
| Total stockholders' equity (deficit) |
|
(3,565,520 |
) |
|
(376,125 |
) |
|
(3,941,645 |
) |
Unaudited condensed consolidated interim statements of changes in stockholders' equity (deficit) as of September 30, 2025
| Line item |
|
As previously reported |
|
|
Adjustment |
|
|
As corrected |
|
| Accumulated deficit |
|
(23,148,134 |
) |
|
(748,625 |
) |
|
(23,896,759 |
) |
| Total stockholders' equity (deficit) |
|
(5,495,295 |
) |
|
(748,625 |
) |
|
(6,243,920 |
) |
|